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Introduction and Objectives: Recent studies indicate a diverse and evolving
CF lung microbiome, but the interaction of these organisms with the host, and
the impact of antimicrobial therapy are poorly understood. Here we study the
inﬂammatory potential and antimicrobial susceptibility of newly identiﬁed bacteria
compared to “typical” CF pathogens.
Methods: CF BAL or sputum was obtained and cultured in Belfast, Chapel Hill and
Dublin and 8−14 isolates each from multiple bacterial genera including Pseudo-
monas, Fusobacteria, Haemophilus, Prevotella, Streptococcus and Veillonella were
studied. The isolates were assessed for activation of the NF-kB pathway in human
airway epithelial cells and for susceptibility to a range of antibiotics (Etest®).
Results: There was profound variability in NF-kB activating potential between
and among genera. Gram negative bacteria including Fusobacteria and Veillonella
tended to be highly stimulatory, similar to Pseudomonas or Burkholderia, while
Prevotella and Gram positive bacteria tended to be less stimulatory. Differences
in antibiotic susceptibility within and between genera and species were apparent
with overall susceptibility ranging from 38% (tobramycin) to 94% (piperacillin/
tazobactam).
Conclusion: We demonstrate wide variability in pro-inﬂammatory potential and
antibiotic susceptibility among the diverse array of bacteria that may be present in
the CF lung. We speculate that these newly identiﬁed organisms inﬂuence the overall
inﬂammatory status of the CF lung, and that these effects are variably modulated
by different antibiotic therapies.
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